Among the gainers, Sun Pharma topped by rising 3.03 per cent as the weak rupee tempted buyers to accumulate shares of pharma exporters.
the Sensex lost 23 points to close at 28,185 levels and the Nifty shed 7 points to end at 8,515 mark.
Most of the session's gains for both the indices were wiped out as investors rushed to book profits ahead of F&O expiry on Thursday and also due to concerns over stretched valuations.
Major global indices like CAC 40, DAX Shanghai Composite, Hang Seng, Nikkei, Straits Times, Sensex, Nifty have lost 1% - 10% in a week
Sun Pharma was the best gainer among Sensex components, surging 6.91 per cent
The NSE 50-share Nifty spurted 97.25 points, or 0.92 per cent, to 10,715.50
Markets under pressure; IT financials grab spotlight.
The broad-based NSE Nifty rose 52.80 points, or 0.50 per cent, to end at 10,530.70
The Union Budget 2016-17 has cheered the NBFC sector
Sensex firm on favourable GDP numbers for FY16.
Markets closed in the red on domestic worries.
Pharma shares were the top gainers led by Lupin after the company received EIR from USFDA for its Goa facility
Investors widened their bets on optimism that upcoming general budget -- to be unveiled next month - would contain incentives for corporates, which will help boost the economy
Reliance ADAG, Tech Mahindra among top recruiters at IIM-A
The Sensex and Nifty remained above their key levels of 36,000 and 10,900 throughout the session, indicating strong investor optimism after a prolonged spell of caution.
Market breadth was weak with 1239 losers and 1078 gainers on the BSE.
Bajaj Auto was the top gainer in the Sensex pack, surging 3.95 per cent followed by Maruti Suzuki at 2.69 per cent.
The BSE Midcap and Smallcap indices have performed better than the front-liners
Profit-booking and selling pressure on below-normal monsoon forecast, marred sentiments, traders said.
Bond issuances dipped 31.4% during January-June
The 50-share NSE Nifty slipped below the 8,200-mark to touch a low of 8,154.45, but settled at 8,170.80, down 90.95 points, or 1.10 per cent
BSE Mid-cap index ended lower by over 2.5% and BSE Small-cap index tumbled over 3%.
Goldman Sachs forecasts real GDP growth to accelerate to 7.9 per cent in FY17 from a projected 7.5 per cent in FY16.
Sensex ended strong, Tata Steel, HUL climb higher.
The 30-share Sensex surged 299 points to close at 28,736 and the 50-share Nifty gained 90 points to end at 8,723.
Profit taking in index heavweights RIL and HDFC weighed on sentiment while ICICI Bank surged 7%.
Mixed global cues and decline in crude oil prices further dent the sentiments.
State owned banks SBI and PNB were the top Nifty gainers along with ICICI Bank and auto shares.
Infosys, Bharti Airtel and ICICI Bank are the only companies who have managed to score 100% on a Composite Disclosure Index
Market participants are now awaiting Thursday's meeting of the European Central Bank
Seven policemen were on Saturday killed and 10 persons were injured in a gunbattle with Naxals in the Maoist hotbed of Sukma district in Chhattisgarh.
The 30-share Sensex is up 253 points at 29,263 and the 50-share Nifty has gained 68 points at 8,829.
The Sensex had bounced back with gains of 94 points or 0.3%
Investors booked profits at higher levels after the Sensex and Nifty hit all-time highs in the previous session.
The services sector, which plays the biggest role in shaping the economy, is facing loads of issues currently. The largest segments, financial and real estate, are struggling to cope with bad debts and low demand for houses.
ICICI Bank, ONGC and Tata Motors contribute to nearly 50% gain seen on the Nifty.
This was the biggest single-day fall for the benchmark index since August 10 when it had fallen by 310 points.
Growth in the eight core sectors jumped to 8.5% in April, due to a sharp pick-up in refinery products and a commensurate rise in electricity generation.
Sensex climbs higher on favourable global cues.
The 50-issue Nifty fell 29.60 points or 0.34 per cent to close at 8,642.55
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances